HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermatology Start-Ups

This article was originally published in Start Up

Executive Summary

Judging from the number of recent well-financed company launches and the size of follow-on rounds for established players, specialty dermatology hasn't lost its allure for investors. Add to that two successful 2004 IPOs--for Barrier Therapeutics Inc. and Cutera Inc.--and it's clear that aesthetic and therapeutic dermatology are still good bases for building specialty pharmaceutical businesses.

You may also be interested in...



Aesthetics: Noninvasive Fat Removal Enters the Scene

New energy-based fat removal technology is emerging as the next frontier in noninvasive energy-based aesthetics, but questions remain as to its mechanism of action in treating fat or cellulite. There is no question that patient demand is strong, and there are a number of products and techniques under development.

Beauty: In the Eye of the Stakeholder

A $12-billion market and growing, the field of aesthetic medicine has exploded with new treatments and techniques for improving and restoring the quality, health and appearance of aging skin. Techniques such as tissue tightening, skin resurfacing, cellulite treatments, dermal augmentation, and fat removal are just some of the new advancements in aesthetic medicine that were highlighted at the 2007 American Academy of Dermatology meeting.

SansRosa Pharmaceutical Development Inc.

SansRosa, a Philadelphia-area start-up focused on dermatological conditions, is reprofiling a group of alpha agonists for use as treatments for rosacea and other disorders. The firm was founded in late 2002 and has so far raised $500,000 from Bioadvance to support its efforts.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel